QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy

Bookmark and Share
Published: 18 Dec 2019
Views: 377
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

Dr Mark Levis speaks to ecancer at the 2019 ASH meeting in Orlando about the post hoc analysis of the QuANTUM-R trial which investigated relapsed/refractory acute myeloid leukaemia (AML) patients with a FLT3-internal tandem duplication (FLT3-ITD) mutation when treated with quizartinib or salvage chemotherapy.

He outlines the trial design and mentions that one of the main focuses was to assess transfusion independence.

Dr Levis reported that an improvement in transfusion independence was seen in the patients who were randomised to receive quizartinib.

He concludes by emphasising the importance of this study, which will hopefully improve the patient's experience when receiving treatment.